Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORER Total Body PET/CT Imaging for Myofascial Pain
NCT05876858Phase 1Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- Jun 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludeoxyglucose f 18 and carbon-11 butanol in myofascial pain syndrome (MPS), sponsored by University of California, Davis. Primary endpoints: HEAL outcome measure and Differentiate Myofascial tissues at 30 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
fludeoxyglucose f 18carbon-11 butanol
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT05876858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876858.